Optimal sequencing of immunotherapy in MSI-H/dMMR colon cancer remains uncertain
In light of recent evidence from the ATOMIC trial, balancing adjuvant and neoadjuvant immunotherapy approaches continues to challenge clinical decision-making.
Sustained quality-of-life benefits reported with first-line antibody-drug conjugate in triple negative breast cancer
Patient-reported outcomes show that datopotamab deruxtecan also improved patient functioning and symptom control compared to chemotherapy
Piccart: “Academic research is losing ground very rapidly”
At a senior stage of her career in oncology, Prof. Martine Piccart remains deeply committed in supporting young oncologists in cancer research
How to sequence antibody–drug conjugates in metastatic breast cancer? Target switching alone may not be the answer
The first prospective phase II trials evaluating TOPO1 ADC after prior TOPO1 ADC therapy confirm the emergence of cross-resistance
Can digital tools improve personalised support for adolescents and young adults with cancer?
Gaps still exist in care and communication for AYA, with failure to address their unique needs
The role of ctDNA surveillance is still uncertain in early breast cancer
Data from two novel studies further support the feasibility of this approach, although its clinical utility has yet to be determined
Towards a chemotherapy-free future in breast cancer?
Recent studies support treatment optimisation for improving patients’ quality of life, but its implementation in clinical practice remains limited
Chemotherapy-free adjuvant treatment preserves quality of life in HER2-positive early breast cancer
A pathological complete response-guided approach enables treatment optimisation in a selected population with HER2-positive breast cancer in the PHERGain-2 study
SERD therapy demonstrates robust anti-proliferative activity in young patients with ER-positive/HER2-negative early breast cancer
Encouraging results with giredestrant support the future use of SERD-based endocrine strategies in this setting
The management of invasive lobular breast cancer is evolving
Advances in molecular profiling and a greater understanding of the underlying biology are reinforcing the concept of a distinct disease from other ER-positive breast cancers